86
Views
0
CrossRef citations to date
0
Altmetric
Systematic Review

Differences in ejection fraction as inclusion criterion in randomized controlled trials among patients with heart failure with reduced ejection fraction: a systematic review

ORCID Icon, ORCID Icon, , , ORCID Icon, , , , , , , , , & show all
Pages 481-484 | Received 19 Dec 2021, Accepted 31 May 2022, Published online: 06 Jun 2022

References

  • Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure. J Card Fail. 2021;23(3): 352–380.
  • Lo KB, Essa H, Wattoo A, et al. Representation of chronic kidney disease in randomized controlled trials among patients with heart failure with reduced ejection fraction: a systematic review. Curr Probl Cardiol. 2021 Nov 14:101047.
  • Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Sep 10;74(10):1376–1414.
  • McDonagh TA, Metra M, Adamo M, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599–3726.
  • Marwick TH Ejection fraction pros and cons: JACC state-of-the-art review. J Am Coll Cardiol. 2018 Nov 6;72(19):2360–2379.
  • Bozkurt B, Ezekowitz J Substance and substrate: LVEF and sex subgroup analyses of PARAGON-HF and PARADIGM-HF trials. Circulation. 2020 Feb 4;141(5):362–366.
  • Solomon SD, Vaduganathan M, Lc B, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020 Feb 4;141(5):352–361.
  • Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018 Jan 1;39(1):26–35.
  • Solomon SD, Claggett B, Lewis EF, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016 Feb 1;37(5):455–462.
  • Hinder M, Yi BA, Langenickel TH Developing drugs for heart failure with reduced ejection fraction: what have we learned from clinical trials? Clin Pharmacol Ther. 2018 May;103(5):802–814.
  • Ponikowski P, Voors AA, Anker SD, et al. 2016 Aug ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 18(8):891–975.
  • Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021 Oct 14;385(16):1451–1461.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.